Schering-Plough: Drugmaker, Heal Thyself
It has a potential blockbuster and a savvy new CEO. With federal probers and Claritin’s expired patent to deal with, it will need both
Geron’s the Biotech of the Day
Geron saw its shares rise $1.72, or 25%, to $8.68 after the company said it has received a patent that could be used in stem-cell research. The process would be used, if it’s ever needed, to provide an additional level of safety for cell therapies made from human embryonic stem cells, the company said.
India ‘to approve GM potato’ The commercial growing of a genetically modified potato which contains nutrients lacking in the diets of many of the poorest is expected to be approved in India within six months.
Genentech’s Next Move
Genentech stunned the cancer world last week with news that its Avastin colon cancer drug extended patients’ lives by five months, proving wrong skeptics who said the blood vessel-blocking drug would never work. Now the biotech pioneer is embarking on a bold strategy to dominate the cancer drug market for decades to come by combining drugs even before they are approved.